143 related articles for article (PubMed ID: 34589947)
1. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by
Ruppert AM; Beau-Faller M; Debieuvre D; Ouafik L; Westeel V; Rouquette I; Mazières J; Bringuier PP; Monnet I; Escande F; Ricordel C; Merlio JP; Janicot H; Lemoine A; Foucher P; Poudenx M; Morin F; Langlais A; Souquet PJ; Barlesi F; Wislez M
JTO Clin Res Rep; 2020 Sep; 1(3):100052. PubMed ID: 34589947
[TBL] [Abstract][Full Text] [Related]
2. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
[TBL] [Abstract][Full Text] [Related]
3. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY
JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Effect of
Wahl SGF; Dai HY; Emdal EF; Berg T; Halvorsen TO; Ottestad AL; Lund-Iversen M; Brustugun OT; Førde D; Paulsen EE; Donnem T; Andersen S; Grønberg BH; Richardsen E
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503114
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.
Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A
Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080
[TBL] [Abstract][Full Text] [Related]
7. Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
Sato K; Akamatsu H; Koh Y; Ogawa K; Isa SI; Ando M; Tamiya A; Kubo A; Kitagawa C; Kawaguchi T; Yamamoto N
BMC Cancer; 2022 Nov; 22(1):1148. PubMed ID: 36348317
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
9. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Implication of
Noordhof AL; Swart EM; Damhuis RAM; Hendriks LEL; Kunst PWA; Aarts MJ; van Geffen WH
JTO Clin Res Rep; 2023 Sep; 4(9):100543. PubMed ID: 37674812
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and prognostic contributors in patients with
Burns EA; Ensor JE; Hsu J; Thomas JS; Olsen RJ; Bernicker EH
J Thorac Dis; 2021 Aug; 13(8):4785-4796. PubMed ID: 34527319
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Outcomes in Advanced
Lee J; Tan AC; Zhou S; Yoon S; Liu S; Masuda K; Hayashi H; Batra U; Kim DW; Goto Y; Tan SH; Wu YL; Lee DH; Tan DSW; Ahn MJ
JTO Clin Res Rep; 2022 Jan; 3(1):100261. PubMed ID: 35024639
[TBL] [Abstract][Full Text] [Related]
13. Characterization of distinct types of
Jia Y; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Qiao M; Luo J; Shi J; Yang H; Wang Y; Xi L; Zhang S; Gao G; Su C; Ren S; Zhou C
Oncol Lett; 2017 Dec; 14(6):6525-6532. PubMed ID: 29163686
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Zhao D; Li H; Mambetsariev I; Mirzapoiazova T; Chen C; Fricke J; Kulkarni P; Villaflor V; Arvanitis L; Hamilton S; Afkhami M; Pillai R; Armstrong B; Erhunmwunsee L; Massarelli E; Sattler M; Amini A; Salgia R
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230855
[TBL] [Abstract][Full Text] [Related]
15. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
16. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.
Sun Y; Li Z; Jian H; Xia L; Lu S
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887766
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and prognostic value of the
Liu SY; Sun H; Zhou JY; Jie GL; Xie Z; Shao Y; Zhang X; Ye JY; Chen CX; Zhang XC; Zhou Q; Yang JJ; Wu YL
Biomark Res; 2020; 8():22. PubMed ID: 32607238
[TBL] [Abstract][Full Text] [Related]
18. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Characteristics and Outcomes for Patients With
Cooper AJ; Muzikansky A; Lennerz J; Narinesingh F; Mino-Kenudson M; Hung YP; Piotrowska Z; Dagogo-Jack I; Sequist LV; Gainor JF; Lin JJ; Heist RS
JTO Clin Res Rep; 2022 Sep; 3(9):100390. PubMed ID: 36118132
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and prognostic analysis of patients with detected
Hashimoto T; Owada Y; Katagiri H; Yakuwa K; Tyo K; Sugai M; Fuzimura I; Utsumi Y; Akiyama M; Nagashima H; Terasaki H; Yanagawa N; Saito H; Sugai T; Maemondo M
Transl Lung Cancer Res; 2023 Sep; 12(9):1862-1875. PubMed ID: 37854155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
